Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)-Reference-Cited by-同舟云学术

Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)

Published:2015-06-02 Issue:1 Volume:152 Page:77-85
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Park Yeon Hee, ,Jung Kyung Hae,Im Seock-Ah,Sohn Joo Hyuk,Ro Jungsil,Ahn Jin-Hee,Kim Sung-Bae,Nam Byung-Ho,Oh Do Youn,Han Sae-Won,Lee Soohyeon,Park In Hae,Lee Keun Seok,Kim Jee Hyun,Kang Seok Yun,Lee Moon Hee,Park Hee Sook,Woo Sook Young,Jung Sin-Ho,Ahn Jin Seok,Im Young-Hyuck

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-015-3450-z/fulltext.html

Reference20 articles.

1. Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA (2003) Health-related quality-of-life measurement in randomized clinical trials in breast cancer–taking stock. J Natl Cancer Inst 95:263–281

2. Lemieux J, Goodwin PJ, Bordeleau LJ, Lauzier S, Theberge V (2011) Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001–2009). J Natl Cancer Inst 103:178–231. doi: 10.1093/jnci/djq508

3. Kramer JA, Curran D, Piccart M, de Haes JC, Bruning P, Klijn J, Van Hoorebeeck I, Paridaens R (2000) Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36:1498–1506

4. Coates A, Gebski V, Signorini D, Murray P, McNeil D, Byrne M, Forbes JF (1992) Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. J Clin Oncol 10:1833–1838

5. Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T, Coleman RE, Calvert HA, Gamucci T, Twelves C, Fargeot P, Bottomley A (2004) Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 40:1021–1030. doi: 10.1016/j.ejca.2004.01.014

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of AC and AC-T Chemotherapy’s Toxicities on Quality of Life Among Women with Breast Cancer in Ethiopia: A Prospective Patient-Reported Outcomes Study;Breast Cancer: Targets and Therapy;2021-02

2. Nanoliposomes as Multidrug Carrier of Gemcitabine/Paclitaxel for the Effective Treatment of Metastatic Breast Cancer Disease: A Comparison with Gemzar and Taxol;Advanced Therapeutics;2020-09-06

3. The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice;Critical Reviews in Oncology/Hematology;2020-09

4. The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer;Breast Cancer Research and Treatment;2019-11-28

5. Optimal designs in three‐level cluster randomized trials with a binary outcome;Statistics in Medicine;2019-06-04